Susquehanna Fundamental Investments LLC Acquires New Shares in LivaNova PLC (NASDAQ:LIVN)

Susquehanna Fundamental Investments LLC bought a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 59,847 shares of the company's stock, valued at approximately $2,772,000. Susquehanna Fundamental Investments LLC owned 0.11% of LivaNova as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in LIVN. Russell Investments Group Ltd. boosted its position in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after purchasing an additional 219 shares in the last quarter. Summit Investment Advisors Inc. boosted its holdings in LivaNova by 1.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company's stock worth $780,000 after acquiring an additional 289 shares in the last quarter. Xponance Inc. grew its stake in shares of LivaNova by 6.1% during the fourth quarter. Xponance Inc. now owns 7,762 shares of the company's stock worth $359,000 after acquiring an additional 445 shares during the last quarter. Mariner LLC increased its holdings in shares of LivaNova by 8.4% during the fourth quarter. Mariner LLC now owns 5,741 shares of the company's stock valued at $266,000 after acquiring an additional 446 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of LivaNova by 0.6% during the fourth quarter. Invesco Ltd. now owns 111,374 shares of the company's stock worth $5,158,000 after buying an additional 667 shares during the period. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on LIVN shares. Mizuho dropped their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price target on shares of LivaNova in a report on Monday, March 17th. Wolfe Research downgraded shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. The Goldman Sachs Group dropped their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $61.17.

LivaNova Trading Down 0.0 %

NASDAQ LIVN traded down $0.01 on Friday, reaching $36.78. 925,924 shares of the company were exchanged, compared to its average volume of 611,981. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $64.48. The stock has a market capitalization of $2.00 billion, a P/E ratio of 87.57 and a beta of 0.90. The business's fifty day moving average price is $37.98 and its 200 day moving average price is $45.64. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.